Loading
Full-Life Technologies makes medicines that carry a strongly radioactive particle, actinium-225, onto cancer cells so the radiation acts at short range. Its lead medicine is being tested in advanced prostate cancer and a second in lung and other solid tumours.
Full-Life Technologies Limited describes itself as a privately held, fully integrated, clinical-stage actinium-based radiopharmaceutical company with operations in Belgium, Germany and China; its website description gives Shanghai as headquarters, and the trial sponsor is its UK subsidiary, Full-Life Technologies UK Limited. It attaches radionuclides to peptides, small molecules and single-domain antibodies. [225Ac]Ac-FL-020, a PSMA-targeted alpha radioconjugate, is in a global phase 1 trial in metastatic castration-resistant prostate cancer (NCT06492122), using an indium-111 labelled version for dosimetry; the company reported preliminary safety and PSA decline data at ESMO in October 2026. [225Ac]Ac-FL-261 targets c-MET and received US FDA IND clearance and Australian clearance in September 2026 for a phase 1/2 trial (NCT07873450) in c-MET overexpressing solid tumours, with an initial focus on non-squamous non-small cell lung cancer. A third, NTSR1-targeted small-molecule radioconjugate is in phase 1 under a collaboration with a partner, and earlier programmes target NPY1R and B7-H3. In August 2026 it completed construction of an actinium-225 manufacturing and radiolabelling facility in Gembloux, Belgium. Its first registered cancer trial, NCT06492122, was posted on ClinicalTrials.gov in July 2024.
Shares Targeted alpha therapy, PSMA, Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer.
Shares Targeted alpha therapy, PSMA, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, PSMA, Metastatic castration-resistant prostate cancer.
Shares PSMA, Metastatic castration-resistant prostate cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares MET, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/